Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

by Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
Published 2016

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

by Pianko S., Zeuzem S., Chuang W.-L., Foster G.R., Sarin S.K., Flisiak R., Lee C.-M., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson I.M.
Published 2014

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

by Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team.
Published 2014